Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANART
2023-509022-22-00Phase 3Authorised
- Sponsor
- Akershus University Hospital
- Start
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of clopidogrel and dalteparin in pancreatic adenocarcinoma (PDAC), venous thromboembolism (VTE) and arterial thrombosis (2 arms), sponsored by Akershus University Hospital. Planned start Aug 2024; status: authorised.
02
Drugs
clopidogreldalteparin
03
Conditions
pancreatic adenocarcinoma (PDAC)venous thromboembolism (VTE)arterial thrombosis
Beyond the preview
Go deeper on 2023-509022-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509022-22-00.